Questex Acquisition Bolsters Fierce Portfolio with The Conference Forum and Versalinx Global Events

In a strategic move set to reshape the landscape of life sciences media and events, Questex has announced the acquisition of The Conference Forum and Versalinx Global Events. This significant expansion of Questex's Healthcare & Life Sciences portfolio promises to enhance the company's ability to connect industry leaders, foster innovation, and accelerate business growth across the pharmaceutical and healthcare sectors.

Expanding Reach and Expertise

The acquisition brings together three powerhouses in the life sciences and healthcare ecosystem. The Conference Forum, known for its research-driven programs, has been a catalyst for uniting clinical leaders, drug development executives, patient advocates, and investors for over a decade. Their flagship events, including DPHARM and PODD, have become synonymous with cutting-edge discussions on clinical trial innovation, patient-centric design, and drug delivery advancements.

Versalinx Global Events, with its focus on commercial and competitive intelligence, adds a new dimension to the Fierce platform. The company's cornerstone event, the Pharma Market Research Conference East, along with its portfolio of U.S. and European events, brings a sophisticated audience of strategy, insights, and commercial acceleration leaders into the fold.

Paul Miller, CEO of Questex, emphasized the significance of the acquisition, stating, "These newly acquired companies significantly expand Questex's Healthcare & Life Sciences portfolio and mirror our mission to bring buyers and sellers together in environments designed for learning, networking and business acceleration."

Enhanced Audience and Network Synergies

The integration of these companies into the Fierce family creates a formidable network of life sciences and healthcare professionals. The Conference Forum's engaged audience of 100,000 qualified pharma professionals will now join Fierce's existing community of over 1.5 million members across media, research, and events.

This consolidation is expected to create unparalleled opportunities for knowledge sharing, networking, and business development. By bringing together diverse segments of the industry, from clinical development to market research and commercialization, Fierce is positioning itself as a comprehensive platform serving every stage of the life sciences value chain.

Leadership and Future Outlook

Both founding leadership teams from The Conference Forum and Versalinx Global Events will join Questex, ensuring continuity and leveraging their expertise in shaping future initiatives. Rhiannon James, Group President of Questex, highlighted the strategic importance of the acquisition: "Fierce has become a powerhouse across the life sciences and healthcare ecosystem—driving innovation, insight and connection. By adding The Conference Forum and Versalinx, we are expanding our reach, deepening our impact, and accelerating our ability to serve every stage of the life sciences value chain."

As the pharmaceutical industry enters a new era of scientific and commercial acceleration, this acquisition positions Fierce to be at the forefront of guiding and convening leaders who are shaping the future of biopharma innovation. From cutting-edge reporting to industry-leading events, Fierce is set to provide a comprehensive platform where industry leaders can connect, learn, and drive the market forward.